NCT03370718View on ClinicalTrials.gov

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

January 12, 2024

Study Completion Date

January 12, 2024

Conditions
Metastatic Carcinoma in the Adrenal CortexStage III Adrenal Cortex Carcinoma AJCC v8Stage IV Adrenal Cortex Carcinoma AJCC v8Unresectable Adrenal Cortex Carcinoma
Interventions
DRUG

Cabozantinib

Given PO

OTHER

Pharmacogenomic Study

Correlative studies

OTHER

Pharmacokinetic Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03370718 - Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma | Biotech Hunter | Biotech Hunter